Quality by Design and Quality by Testing

In the bioprocessing world, ensuring product quality is not just a goal but an absolute necessity. The stakes are high: manufactured medicines impact patient safety and treatment efficacy. With the advancement of biotechnological methods and increased regulatory scrutiny, the industry is perpetually searching for methodologies that guarantee the highest quality standards. The field has undergone a conceptual evolution from Quality by Testing (QbT) to Quality by Design (QbD) as the guiding paradigm in the development, production, and regulation of bioprocesses.

 

The QbT thought process is rooted in post-production verification and has its merits but also has inherent limitations. It is a reactive process that often needs to be more proactive in the production cycle to be effective against quality issues. On the flip side, Quality by Design (QbD) is a proactive approach focusing on understanding processes and designing quality into the product from the beginning of development.

 

This blog post ventures into the depths of these two disparate approaches to quality, evaluating their principles, methodologies, and impacts on bioprocessing. We will dissect the advantages and disadvantages of QbD and QbT and reflect on the transformative effect of QbD on regulatory frameworks and industry standards. Join us as we explore how the shift towards a Quality Design philosophy is revolutionizing the field, ensuring that quality is tested for and built into every facet of the bioprocessing pipeline.

 

Quality by Testing (QbT)

Quality by Testing (QbT), as the name suggests, is extensive testing of the final product to ensure it meets predefined quality standards. This methodology was the cornerstone of pharmaceutical and bioprocessing quality control for many years. In QbT, the name of the game is conformity with the specifications of the drug products at the end of the manufacturing line. Although rigorous release testing of drug products is required, QbT reasons that a high degree of testing can catch and eliminate any discrepancies or defects before the product reaches the market.

 

The QbT Process:

At its core, the QbT paradigm involves a series of steps:

1.) Manufacturing – The product is manufactured following established procedures, with quality considerations often limited to adherence to standard operating procedures (SOPs) and good manufacturing practices (GMP)

2.) Testing – Rigorous testing of the finished product focuses on attributes such as purity, potency, and stability. This testing is often thorough, time-consuming, and costly.

3.) Release – Provided the product passes all tests, it is deemed of appropriate quality and released to the market.

 

Limitations of QbT:

While QbT has been successful in producing safe and effective biologics for years, it has limitations:

1.) Reactive Nature: QbT is inherently reactive, with issues often being identified after the fact, leading to wastage, recalls, or, in the worst cases, patient harm.

2.) Limited Process Understanding and Testing Over-Reliance: It focuses on end-product testing without necessarily improving the underlying manufacturing processes or addressing variability within those processes.

3.) Inefficient Resource Allocation: Over-testing of drug products can be a significant cost that reduces process profitability. Further, hyper-focus on the final product can lead to missed opportunities for process improvements.

4.) Regulatory Risks: Any failure to meet the specifications can cause severe regulatory ramifications, including market withdrawal and damaged reputation.

 

Despite its limitations, QbT remains a part of the industry’s quality landscape, especially for established processes where change can be expensive or regulatory re-approval burdensome. However, as the industry moves forward with more complex biologics and tighter regulations, the voice for a more robust and scientifically sound quality assurance model has ushered in the era of Quality by Design (QbD).

In the following section, we will explore the QbD methodology and how it is poised to redefine the concept of quality in bioprocessing, offering a preventive rather than retrospective assurance of quality.

 

Quality by Design (QbD)

QbD is a strategic approach that has become an advanced method for achieving quality in bioprocessing. Unlike QbT, QbD is a proactive process that begins at the earliest stages of product development and continues throughout the product lifecycle. The QbD framework encourages a deeper understanding of processes and their impact on the final product’s quality. QbD is based on the premise that quality should not be inspected into products; instead, it should be inherently built into the design and development phases.

 

Principles of QbD:

QbD integrates the following critical principles into biologics manufacturing:

1.) Risk Management: Identifying and mitigating potential risks upfront ensures that the process stays in control and that the product meets the intended quality attributes.

2.) Process Understanding: A comprehensive understanding of both the product and the process is crucial and allows for robust manufacturing operations design.

3.) Design Space: Defining the multidimensional space that outlines the range within which process parameters can vary without affecting the quality.

4.) Control Strategy: Implementing a planned set of controls derived from understanding how process parameters affect product quality.

 

Implementing QbD in Bioprocessing:

QbD is an iterative process involving several steps:

• Define Quality Target Product Profile (QTPP): The foundation of QbD is the QTPP, which is a clear statement of the desired characteristics of the final product that guides process development.
• Identify Critical Quality Attributes (CQAs): These are the physical, chemical, biological, or microbiological characteristics within an appropriate limit to ensure the desired product quality.
• Perform Risk Assessment: Using tools like Failure Mode and Effects Analysis (FMEA) to analyze processes and identify where and how they might fail, impacting CQAs.
• Establish a Design Space and Control Strategy: A series of process characterization studies define acceptable ranges for process parameters that ensure that the processes remain within this space to produce quality products consistently.
• Continual Improvement: QbD is not a one-time effort; it encourages ongoing monitoring and adaptation to enhance process understanding and performance.

Benefits of QbD:

• Enhanced Productivity: By understanding the process deeply, manufacturers can optimize it, thereby increasing yields and reducing waste.
• Improved Product Consistency: Consistent quality is achieved batch after batch with a more profound knowledge of the process and control strategies in place.
• Regulatory Flexibility: Regulatory bodies may offer certain flexibility within the approved design space without requiring additional regulatory submission.
• Cost Efficiency: Over time, by reducing reliance on end-product testing and batch failures, QbD leads to overall cost savings and more efficient resource use.

QbD is transforming bioprocessing by ingraining quality within the product from conception to delivery, leading to safer and more reliable biopharmaceuticals. The adoption of QbD principles meets rigorous regulatory standards and aligns with the industry’s shift towards a more scientific and risk-based approach to quality management.